Breaking barriers to CAR T-cell therapy: The vision for expanding patient access

Only approximately two out of 10 people in the US and three out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy. So it is that the CAR-T Vision Coalition aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.

At ASCO 2025, web editor Nicole Raleigh had the pleasure of speaking with Professor Dr Jason Westin, lead of the Lymphoma & Myeloma Service Line at the MD Anderson Cancer Center, as well as director of Lymphoma Clinical Research and section chief of Aggressive and Indolent Lymphomas, about the Coalition, and more.

The conversation explores issues of patient access and a projected roadmap for measurable, active outcomes from the CAR-T Vision, as well as key takeaways from ASCO 2025.

Watch this and other discussions with oncology experts from onsite in Chicago at this year’s Congress here.